NON HODGKIN LYMPHOMA (NHL)
Clinical trials for NON HODGKIN LYMPHOMA (NHL) explained in plain language.
Never miss a new study
Get alerted when new NON HODGKIN LYMPHOMA (NHL) trials appear
Sign up with your email to follow new studies for NON HODGKIN LYMPHOMA (NHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost CAR-T safety in lymphoma patients
Disease control Recruiting nowThis early-stage trial tests whether giving radiation therapy and the antibiotic vancomycin before CAR-T cell therapy is safe and doable for people with large B-cell lymphoma. About 14 adults whose lymphoma has not responded or has come back will receive this combination. The goa…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: PHASE1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Double-Target CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis phase 1/2 trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to improve treatment for people with relapsed or refractory B-cell cancers like lymphoma and leukemia. The study will enroll up to 100 adults and eva…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for tough lymphomas? early trial of NB02 begins
Disease control Recruiting nowThis early-phase trial is testing a new drug called NB02 (posseltinib) in 9 adults with certain types of Non-Hodgkin lymphoma (follicular, mantle cell, or marginal zone) that have returned or not responded to at least two prior treatments. The main goals are to find a safe dose a…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: PHASE1 • Sponsor: NOBO Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called LV009 for people with certain blood cancers (lymphoma and leukemia) that have come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target cancer cells. The main goal is to c…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: EARLY_PHASE1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New 'Two-Pronged' CAR-T attack shows promise for tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 26, 2026 14:38 UTC